<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Pazopanib</strong></td></tr><tr><th>Accession Number</th><td><strong>DB06589</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was <span class="caps">FDA</span> approved on October 19, 2009.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB06589/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB06589/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06589.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06589.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06589.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06589.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06589.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB06589">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Pazopanib Hydrochloride </strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000135/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000135/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: MQHIQUBXFFAOMK-UHFFFAOYSA-N</li>
              <li>Monoisotopic Mass: 473.140071444</li>
              <li>Average Mass: 473.979</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000135">DBSALT000135</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Votrient </td><td>GlaxoSmithKline</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>444731-52-6</td></tr><tr><th>Weight</th><td>Average: 437.518<br>Monoisotopic: 437.163393705</td></tr><tr><th>Chemical Formula</th><td>C<sub>21</sub>H<sub>23</sub>N<sub>7</sub>O<sub>2</sub>S</td></tr><tr><th>InChI Key</th><td>CUIHSIWYWATEQL-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzene-1-sulfonamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Benzenesulfonamides</td></tr><tr><th>Direct parent</th><td>Aminobenzenesulfonamides</td></tr><tr><th>Alternative parents</th><td>Indazoles; Toluenes; Aminopyrimidines and Derivatives; Sulfonamides; Sulfonyls; Pyrazoles; Tertiary Amines; Polyamines; Secondary Amines</td></tr><tr><th>Substituents</th><td>indazole; benzopyrazole; aminopyrimidine; toluene; pyrimidine; sulfonic acid derivative; sulfonyl; azole; sulfonamide; pyrazole; tertiary amine; polyamine; secondary amine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy) </td></tr><tr><th>Pharmacodynamics</th><td>Pazopanib is a synthetic indazolylpyrimidine and reaches steady state concentrations of &gt;15 &#956;g/ml. This concentration is high enough to observe maximal inhibition of VEGFR2 phosphorylation and some anti-tumour activity (concentration required to inhibit receptors is 0.01 - 0.084 &#956;mol/L). A reduction in tumour blood flow, increased tumour apoptosis, inhibition of tumour growth, reduction in tumour interstitial fluid pressure, and hypoxia in cancer cells can be observed in patients receiving treatment. </td></tr><tr><th>Mechanism of action</th><td>Pazopanib is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived growth factor receptor-beta, and c-kit. These receptor targets are part of the angiogenesis pathway that facilitates the formation of tumour blood vessel for tumour survival and growth. </td></tr><tr><th>Absorption</th><td>Absorption of pazopanib in cancer patients is slow and incomplete. In patients with solid tumour, over a dose range of 50-2000 mg, absorption is nonlinear. Significant accumulation of pazopanib can also be observed in patients receiving 800 mg once daily for 22 days. Crushing tablets may increase exposure (increase in Cmax and AUC, while Tmax decreases by 2 hours). 
Bioavailability, oral tablet 800 mg, cancer patient = 21%;
Bioavailability may be low due to incomplete absorption from the gastrointestinal tract. The major circulating component of the drug in the systemic is pazopanib, and not its metabolites. 
Mean maximum plasma concentration= 58.1 &#181;g/mL;
Mean AUC= 1037 &#181;g &#183; h/mL; </td></tr><tr><th>Volume of distribution</th><td><p>Vd steady state, IV administration 5 mg, cancer patient = 11.1 L (range of 9.15 &#8211; 13.4)</p></td></tr><tr><th>Protein binding</th><td>&gt;99% protein bound, independent of concentrations over a range of 10-100 &#956;g/mL. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8. Metabolites are less active than pazopanib (10 to 20-fold less active). Three of its metabolites can be observed in the systemic and account for </p></td></tr><tr><th>Route of elimination</th><td>Primarily excreted via feces (82.2%) and to a negligible extent via urine (</td></tr><tr><th>Half life</th><td>35 hours. Oral absorption is not the rate limiting step of elimination from the plasma. </td></tr><tr><th>Clearance</th><td><p>CL, cancer patient, IV administration 5 mg = 4mL/min <br>
Half of the absorbed dose is cleared via oxidative metabolism.</p></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8788</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.8307</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8126</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8152</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7797</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8008</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6024</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5065</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7779</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6811</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5385</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.5668</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6543
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8567
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9935
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.3961 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9219
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7129
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Glaxosmithkline</li></ul></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>200 mg </td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Clarithromycin is a strong inhibitor of CYP3A4 thus increasing exposure of pazopanib. </td></tr><tr><td><a href="/drugs/DB00872">Conivaptan</a></td><td>CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib. Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible. If it is not possible to avoid such a combination, reduce pazopanib dose to 400 mg. Further dose reductions may also be required. </td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Pazopanib, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid concurrent therapy.</td></tr><tr><td><a href="/drugs/DB01181">Ifosfamide</a></td><td>Ifosfamide decreases plasma levels of pazopanib. </td></tr><tr><td><a href="/drugs/DB00762">Irinotecan</a></td><td>Irinotecan is an uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) substrate and serum concentrations may increase if administered concurrently with pazopanib, an UGT1A1 inhibitor. </td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB08820">Ivacaftor</a></td><td>Inhibits p-glycoprotein and affects heptatic metabolism via CYP3A4 therefore increases levels of pazopanib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Ketoconazole is a strong inhibitor of CYP3A4 thus increasing exposure of pazopanib by 120% in healthy subjects. </td></tr><tr><td><a href="/drugs/DB01259">Lapatinib</a></td><td>Lapatinib is a weak inhibitor of CYP3A4, BCRP, and p-glycoprotein and may increase exposure of pazopanib. AUC and Cmax increase by 50-60%. </td></tr><tr><td><a href="/drugs/DB06708">Lumefantrine</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB00904">Ondansetron</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01229">Paclitaxel</a></td><td>Pazopanib increases exposure of paclitaxel </td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Concomitant therapy with a CYP3A4 inducer may decrease exposure of pazopanib. </td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Ritonavir is a strong inhibitor of CYP3A4 thus increasing exposure of pazopanib. </td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB00641">Simvastatin</a></td><td>Elevated liver enzyme levels may be observed with concomitant therapy with pazopanib. Monitor closely for adverse effects. </td></tr><tr><td><a href="/drugs/DB00539">Toremifene</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00246">Ziprasidone</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid drinking grapefruit juice as it is a CYP 3A4 inhibitor and will increase exposure of pazopanib</li>
<li>Bioavailability increases with food. Take pazopanib on empty stomach. </li></ul></td></tr></tbody></table>